RxDoctor Payments DataLook up a doctor →

Robert Wooten, MD

Gastroenterology · Germantown, TNNPI 1437134020

Payments from drug & device makers

$19,079in general payments, 2019–2025

Across 808 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Intercept Pharmaceuticals, Inc.$802
  • Sanofi$678
  • plus $8K from 37 others

What the payments were for

  • Food & beverage$18,92299%
  • Education$1571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,079 in reported general payments places this provider in the 80th percentile of 336 gastroenterology providers in Tennessee.

See all gastroenterology providers in Tennessee

Medicare billing

Part B allowed, 2024
$197,038
Medicare patients
850
Services billed
1,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$417,586
CreonLipase/Protease/Amylase19$36,331
LinzessLinaclotide27$28,970
ClenpiqSod Picosulf/Mag Ox/Citric Ac145$23,504
TrulancePlecanatide20$15,841
Dexlansoprazole DrDexlansoprazole17$5,643
Pantoprazole Sodium350$3,158
Mesalamine11$2,726
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates38$2,551
Omeprazole103$1,244
Esomeprazole Magnesium22$517
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$382
Dicyclomine Hcl22$371
Famotidine29$273
Ondansetron Hcl15$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,427$417,58615 claims
AbbVieCreon, Linzess$4,498$65,30046 claims
Ferring Pharmaceuticals Inc.Clenpiq$323$23,504145 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$2,495$15,84120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 336 gastroenterology providers in Tennessee.

Other gastroenterology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →